• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4661586)   Today's Articles (0)   Subscriber (51519)
Download
Number Citation Analysis
1
Bauss F, Lechmann M, Krippendorff BF, Staack R, Herting F, Festag M, Imhof-Jung S, Hesse F, Pompiati M, Kollmorgen G, da Silva Mateus Seidl R, Bossenmaier B, Lau W, Schantz C, Stracke JO, Brinkmann U, Onda M, Pastan I, Bosslet K, Niederfellner G. Characterization of a re-engineered, mesothelin-targeted Pseudomonas exotoxin fusion protein for lung cancer therapy. Mol Oncol 2016;10:1317-29. [PMID: 27507537 PMCID: PMC5423209 DOI: 10.1016/j.molonc.2016.07.003] [Citation(s) in RCA: 46] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2016] [Revised: 06/27/2016] [Accepted: 07/06/2016] [Indexed: 10/21/2022]  Open
2
Brünker P, Wartha K, Friess T, Grau-Richards S, Waldhauer I, Koller CF, Weiser B, Majety M, Runza V, Niu H, Packman K, Feng N, Daouti S, Hosse RJ, Mössner E, Weber TG, Herting F, Scheuer W, Sade H, Shao C, Liu B, Wang P, Xu G, Vega-Harring S, Klein C, Bosslet K, Umaña P. RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis. Mol Cancer Ther 2016;15:946-57. [PMID: 27037412 DOI: 10.1158/1535-7163.mct-15-0647] [Citation(s) in RCA: 98] [Impact Index Per Article: 10.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2015] [Accepted: 01/18/2016] [Indexed: 11/16/2022]
3
Niederfellner G, Bauss F, Imhof-Jung S, Hesse F, Kronenberg S, Staak R, Lechmann M, Krippendorff B, Richter W, Mateus R, Kollmorgen G, Brinkmann U, Onda M, Pastan I, Bosslet K. Abstract 4510: RG7787 - a novel de-immunized PE based fusion protein for therapy of mesothelin-positive solid tumors. Cancer Res 2014. [DOI: 10.1158/1538-7445.am2014-4510] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
4
Alewine C, Xiang L, Yamori T, Niederfellner G, Bosslet K, Pastan I. Efficacy of RG7787, a next-generation mesothelin-targeted immunotoxin, against triple-negative breast and gastric cancers. Mol Cancer Ther 2014;13:2653-61. [PMID: 25239937 DOI: 10.1158/1535-7163.mct-14-0132] [Citation(s) in RCA: 64] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
5
Schmittnaegel M, Hoffmann E, Mundigl O, Niederfellner G, Bosslet K, Umana P, Levitsky V, Klein C, Knoetgen H. Abstract B69: Novel MHC class I antibody fusions for cancer treatment. Cancer Res 2013. [DOI: 10.1158/1538-7445.tumimm2012-b69] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
6
Guinn BA, Bosslet K, Lee C, Richardson D, Orchard K. Expression of CD66 in non-Hodgkin lymphomas and multiple myeloma. Eur J Haematol 2011;87:554-5. [PMID: 21883478 DOI: 10.1111/j.1600-0609.2011.01698.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
7
Gao J, Chesebrough JW, Incognito L, Coats S, Bosslet K, Jallal B, Chang YS. Abstract 1757: MEDI-573, an IGF-I/II neutralizing human antibody inhibits both IGF-1R and IR-A signaling pathways. Cancer Res 2011. [DOI: 10.1158/1538-7445.am2011-1757] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
8
Gao J, Chesebrough JW, Cartlidge SA, Ricketts SA, Incognito L, Veldman-Jones M, Blakey DC, Tabrizi M, Jallal B, Trail PA, Coats S, Bosslet K, Chang YS. Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth. Cancer Res 2011;71:1029-40. [PMID: 21245093 DOI: 10.1158/0008-5472.can-10-2274] [Citation(s) in RCA: 103] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
9
Siemeister G, Luecking U, Wagner C, Detjen K, Mc Coy C, Bosslet K. Molecular and pharmacodynamic characteristics of the novel multi-target tumor growth inhibitor ZK 304709. Biomed Pharmacother 2006;60:269-72. [PMID: 16887322 DOI: 10.1016/j.biopha.2006.06.003] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2006] [Indexed: 11/24/2022]  Open
10
Siemeister G, Briem H, Brumby T, Haberey M, Jautelat R, Krüger M, Lücking U, Reichel A, Schäfer M, Bosslet K. 416 Simultaneous targeting of tumor cell proliferation and tumor-induced neoangiogenesis by the novel CDK2/VEGF-RTK dual pathway inhibitor ZK-CDK. EJC Suppl 2004. [DOI: 10.1016/s1359-6349(04)80424-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]  Open
11
Schirrmacher V, Bosslet K. Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. X. Immunoselection of tumor variants differing in tumor antigen expression and metastatic capacity. Int J Cancer 2004;25:781-8. [PMID: 14768708 DOI: 10.1002/ijc.2910250614] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
12
Hoffmann J, Lichtner R, Fuhrmann U, Hess-Stumpp H, Siemeister G, Cleve A, Neef G, Parczyk K, Schneider M, Bosslet K. P48 Progesterone receptor antagonists an alternative for breast cancer prevention. EJC Suppl 2004. [DOI: 10.1016/s1359-6349(04)90163-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]  Open
13
Seiler FR, Gronski P, Kurrle R, Lüben G, Harthus HP, Ax W, Bosslet K, Schwick HG. Monoclonal Antibodies: Their Chemistry, Functions, and Possible Uses. ACTA ACUST UNITED AC 2003. [DOI: 10.1002/anie.198501393] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
14
Mürdter TE, Friedel G, Backman JT, McClellan M, Schick M, Gerken M, Bosslet K, Fritz P, Toomes H, Kroemer HK, Sperker B. Dose optimization of a doxorubicin prodrug (HMR 1826) in isolated perfused human lungs: low tumor pH promotes prodrug activation by beta-glucuronidase. J Pharmacol Exp Ther 2002;301:223-8. [PMID: 11907177 DOI: 10.1124/jpet.301.1.223] [Citation(s) in RCA: 39] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]  Open
15
Papot S, Combaud D, Bosslet K, Gerken M, Czech J, Gesson JP. Synthesis and cytotoxic activity of a glucuronylated prodrug of nornitrogen mustard. Bioorg Med Chem Lett 2000;10:1835-7. [PMID: 10969980 DOI: 10.1016/s0960-894x(00)00353-x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
16
Mennel HD, Bosslet K, Geissel H, Bauer BL. Immunohistochemically visualized localisation of gangliosides Glac2 (GD3) and Gtri2 (GD2) in cells of human intracranial tumors. EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY : OFFICIAL JOURNAL OF THE GESELLSCHAFT FUR TOXIKOLOGISCHE PATHOLOGIE 2000;52:277-85. [PMID: 10987178 DOI: 10.1016/s0940-2993(00)80046-9] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
17
Desbene S, Van HD, Michel S, Tillequin F, Koch M, Schmidt F, Florent JC, Monneret C, Straub R, Czech J, Gerken M, Bosslet K. Application of the ADEPT strategy to the MDR resistance in cancer chemotherapy. ANTI-CANCER DRUG DESIGN 1999;14:93-106. [PMID: 10405636] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/13/2023]
18
Florent JC, Dong X, Gaudel G, Mitaku S, Monneret C, Gesson JP, Jacquesy JC, Mondon M, Renoux B, Andrianomenjanahary S, Michel S, Koch M, Tillequin F, Gerken M, Czech J, Straub R, Bosslet K. Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy. J Med Chem 1998;41:3572-81. [PMID: 9733483 DOI: 10.1021/jm970589l] [Citation(s) in RCA: 53] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
19
Mürdter TE, Sperker B, Bosslet K, Fritz P, Kroemer HK. Simultaneous high-performance liquid chromatographic determination of a glucuronyl prodrug of doxorubicin, doxorubicin and its metabolites in human lung tissue. JOURNAL OF CHROMATOGRAPHY. B, BIOMEDICAL SCIENCES AND APPLICATIONS 1998;709:289-95. [PMID: 9657226 DOI: 10.1016/s0378-4347(98)00079-6] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
20
Bosslet K, Straub R, Blumrich M, Czech J, Gerken M, Sperker B, Kroemer HK, Gesson JP, Koch M, Monneret C. Elucidation of the mechanism enabling tumor selective prodrug monotherapy. Cancer Res 1998;58:1195-201. [PMID: 9515805] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
21
Mürdter TE, Sperker B, Kivistö KT, McClellan M, Fritz P, Friedel G, Linder A, Bosslet K, Toomes H, Dierkesmann R, Kroemer HK. Enhanced uptake of doxorubicin into bronchial carcinoma: beta-glucuronidase mediates release of doxorubicin from a glucuronide prodrug (HMR 1826) at the tumor site. Cancer Res 1997;57:2440-5. [PMID: 9192823] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
22
Sperker B, Mürdter TE, Schick M, Eckhardt K, Bosslet K, Kroemer HK. Interindividual variability in expression and activity of human beta-glucuronidase in liver and kidney: consequences for drug metabolism. J Pharmacol Exp Ther 1997;281:914-20. [PMID: 9152401] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]  Open
23
Schmidt F, Florent J, Monneret C, Straub R, Czech J, Gerken M, Bosslet K. Glucuronide prodrugs of hydroxy compounds for antibody directed enzyme prodrug therapy (ADEPT) : A phenol nitrogen mustard carbamate. Bioorg Med Chem Lett 1997. [DOI: 10.1016/s0960-894x(97)00157-1] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
24
Rabes HM, Gabbert HE, Grunicke H, Lutz WK, Bornkamm G, Brandner G, Bosslet K, Rajewsky MF, Eisenbrand G, Schneider MR. 8th International AEK symposium of the Division of Experimental Cancer Research of the German Cancer Society. 29-31 March 1995, Heidelberg, Germany. J Cancer Res Clin Oncol 1995;121:683-90. [PMID: 7593133 DOI: 10.1007/bf01218527] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
25
Hanisch FG, Stadie T, Bosslet K. Monoclonal antibody BW835 defines a site-specific Thomsen-Friedenreich disaccharide linked to threonine within the VTSA motif of MUC1 tandem repeats. Cancer Res 1995;55:4036-40. [PMID: 7545084] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
PrevPage 1 of 4 1234Next
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Excel